Company · Kirkland, Quebec, Canada
Pfizer Canada Ulc
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 580
- 278 authorized now
- Natural health products
- 0
- 0 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 1,004
Drug products
Authorized products first.
| Name | DIN | Status | Status since |
|---|---|---|---|
| ABRILADA | 02511045 | Marketed | |
| ABRILADA | 02511053 | Marketed | |
| ABRILADA | 02511061 | Marketed | |
| ABRYSVO | 02544040 | Marketed | |
| ADCETRIS | 02401347 | Marketed | |
| ALESSE 21 | 02236974 | Marketed | |
| ALESSE 28 | 02236975 | Marketed | |
| ARICEPT | 02232043 | Marketed | |
| ARICEPT | 02232044 | Marketed | |
| AROMASIN | 02242705 | Marketed | |
| ARTHROTEC 50 | 01917056 | Marketed | |
| ARTHROTEC 75 | 02229837 | Marketed | |
| ATGAM | 02234470 | Marketed | |
| BACTERIOSTATIC SODIUM CHLORIDE INJECTION USP | 00037818 | Marketed | |
| BACTERIOSTATIC WATER FOR INJECTION USP | 00038202 | Marketed | |
| BACTERIOSTATIC WATER FOR INJECTION USP-PRE-FILLED SYRINGE | 02215721 | Marketed | |
| BENEFIX | 02293773 | Marketed | |
| BENEFIX | 02293781 | Marketed | |
| BENEFIX | 02293803 | Marketed | |
| BENEFIX | 02392984 | Marketed | |
| BENVYON | 02524309 | Marketed | |
| BESPONSA | 02473909 | Marketed | |
| BICILLIN L-A | 02291924 | Marketed | |
| BLEOMYCIN FOR INJECTION USP | 02131692 | Marketed | |
| BORTEZOMIB FOR INJECTION | 02467003 | Marketed | |
| BOSULIF | 02419149 | Marketed | |
| BOSULIF | 02419157 | Marketed | |
| BRAFTOVI | 02513099 | Marketed | |
| BREVICON 0.5/35 TABLETS (21-DAY PACK) | 02187086 | Marketed | |
| BREVICON 0.5/35 TABLETS (28-DAY PACK) | 02187094 | Marketed | |
| BREVICON 1/35 TABLETS (21-DAY PACK) | 02189054 | Marketed | |
| BREVICON 1/35 TABLETS (28-DAY PACK) | 02189062 | Marketed | |
| CALCIUM CHLORIDE INJECTION USP | 00294748 | Marketed | |
| CARBOCAINE 1% | 02241999 | Marketed | |
| CARBOCAINE 1% | 02242000 | Marketed | |
| CARBOCAINE 2% | 02242001 | Marketed | |
| CARBOPLATIN INJECTION BP | 02126680 | Marketed | |
| CAVERJECT STERILE POWDER | 02215756 | Marketed | |
| CAVERJECT STERILE POWDER - PWS 23.2MCG/VIAL | 02215187 | Marketed | |
| CIBINQO | 02528363 | Marketed | |
| CIBINQO | 02528371 | Marketed | |
| CIBINQO | 02528398 | Marketed | |
| CISPLATIN INJECTION BP | 02126613 | Marketed | |
| COLESTID TABLETS | 02132680 | Marketed | |
| CORTEF | 00030910 | Marketed | |
| CORTEF | 00030929 | Marketed | |
| CORVERT | 02242470 | Marketed | |
| CYKLOKAPRON 100 MG/ML | 02064413 | Marketed | |
| CYKLOKAPRON 500 MG | 02064405 | Marketed | |
| CYTARABINE INJECTION | 02126656 | Marketed | |
| CYTOMEL | 01919466 | Marketed | |
| CYTOMEL | 01919458 | Marketed | |
| DACARBAZINE FOR INJECTION BP | 02241445 | Marketed | |
| DALACIN C FLAVOURED GRANULES | 00225851 | Marketed | |
| DAURISMO | 02498472 | Marketed | |
| DAURISMO | 02498480 | Marketed | |
| DEFEROXAMINE MESYLATE FOR INJECTION | 02241600 | Marketed | |
| DEFEROXAMINE MESYLATE FOR INJECTION | 02247022 | Marketed | |
| DEPO-MEDROL | 00030767 | Marketed | |
| DEPO-MEDROL | 00030759 | Marketed | |
| DEPO-MEDROL | 01934333 | Marketed | |
| DEPO-MEDROL | 01934341 | Marketed | |
| DEPO-MEDROL | 01934325 | Marketed | |
| DEPO-MEDROL WITH LIDOCAINE | 00260428 | Marketed | |
| DEPO-PROVERA | 02523493 | Marketed | |
| DEXTROSE INJECTION USP | 02468514 | Marketed | |
| DIFLUCAN | 00891835 | Marketed | |
| DIFLUCAN | 02024152 | Marketed | |
| DIFLUCAN ONE | 02141442 | Marketed | |
| DOCETAXEL INJECTION USP | 02361957 | Marketed | |
| DOSTINEX | 02242471 | Marketed | |
| DOXORUBICIN | 02410397 | Marketed | |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 02194465 | Marketed | |
| DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP | 02194473 | Marketed | |
| DUAVIVE | 02432854 | Marketed | |
| ELREXFIO | 02543559 | Marketed | |
| ELREXFIO | 02543567 | Marketed | |
| EPINEPHRINE INJECTION USP | 00710814 | Marketed | |
| EPINEPHRINE INJECTION USP | 00721891 | Marketed | |
| ERAXIS | 02330695 | Marketed | |
| ESTRING | 02168898 | Marketed | |
| EUCRISA | 02476991 | Marketed | |
| FRAGMIN | 02132648 | Marketed | |
| FRAGMIN | 02132621 | Marketed | |
| FRAGMIN | 02231171 | Marketed | |
| FRAGMIN | 02352648 | Marketed | |
| FRAGMIN | 02352656 | Marketed | |
| FRAGMIN | 02352664 | Marketed | |
| FRAGMIN | 02352672 | Marketed | |
| FRAGMIN | 02352680 | Marketed | |
| FRAGMIN | 02430789 | Marketed | |
| FRAGMIN | 02494582 | Marketed | |
| GEMCITABINE INJECTION | 02402831 | Marketed | |
| GENOTROPIN | 02401703 | Marketed | |
| GENOTROPIN | 02401711 | Marketed | |
| GENOTROPIN | 02401746 | Marketed | |
| GENOTROPIN | 02401754 | Marketed | |
| GENOTROPIN | 02401762 | Marketed | |
| GENOTROPIN | 02401770 | Marketed | |
| GENOTROPIN | 02401789 | Marketed | |
| GENOTROPIN | 02401797 | Marketed | |
| GENOTROPIN | 02401800 | Marketed | |
| GENOTROPIN | 02401819 | Marketed | |
| GENOTROPIN | 02401827 | Marketed | |
| GENOTROPIN | 02401835 | Marketed | |
| HEMABATE | 02230417 | Marketed | |
| HEPARIN SODIUM IN 0.9% SODIUM CHLORIDE INJECTION | 01990748 | Marketed | |
| HEPARIN SODIUM INJECTION USP | 02382326 | Marketed | |
| IBRANCE | 02493535 | Marketed | |
| IBRANCE | 02493543 | Marketed | |
| IBRANCE | 02493551 | Marketed | |
| IDARUBICIN | 02410028 | Marketed | |
| INLYTA | 02389630 | Marketed | |
| INLYTA | 02389649 | Marketed | |
| IRINOTECAN HYDROCHLORIDE INJECTION USP | 02258218 | Marketed | |
| IXIFI | 02523191 | Marketed | |
| LEDERLE LEUCOVORIN | 02170493 | Marketed | |
| LEUCOVORIN CALCIUM INJECTION USP | 02182998 | Marketed | |
| LEUCOVORIN CALCIUM INJECTION USP | 02183005 | Marketed | |
| LEVOFLOXACIN IN 5% DEXTROSE INJECTION | 02314932 | Marketed | |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 01901915 | Marketed | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 00436208 | Marketed | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 00884154 | Marketed | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 01901982 | Marketed | |
| LITFULO | 02543532 | Marketed | |
| LMD 10% IN 0.9% SODIUM CHLORIDE | 00224227 | Marketed | |
| LMD 10% IN DEXTROSE 5% | 00224235 | Marketed | |
| LOMOTIL | 00036323 | Marketed | |
| LONITEN 10MG | 00514500 | Marketed | |
| LONITEN 2.5MG | 00514497 | Marketed | |
| LORBRENA | 02485966 | Marketed | |
| LORBRENA | 02485974 | Marketed | |
| MANNITOL INJECTION USP | 00038024 | Marketed | |
| MARCAINE | 02241917 | Marketed | |
| MARCAINE | 02305909 | Marketed | |
| MARCAINE E | 02241915 | Marketed | |
| MARCAINE E | 02241916 | Marketed | |
| MEDROL | 00036129 | Marketed | |
| MEDROL | 00030988 | Marketed | |
| MEKTOVI | 02513080 | Marketed | |
| METHOTREXATE INJECTION USP | 02182777 | Marketed | |
| METHOTREXATE INJECTION USP | 02182947 | Marketed | |
| METHOTREXATE INJECTION USP | 02182955 | Marketed | |
| METHOTREXATE INJECTION USP | 02182971 | Marketed | |
| METHOTREXATE TABLETS, USP | 02182750 | Marketed | |
| MIDAZOLAM INJECTION USP | 02382342 | Marketed | |
| MIDAZOLAM INJECTION USP | 02382350 | Marketed | |
| MIDAZOLAM INJECTION USP | 02382377 | Marketed | |
| MIDAZOLAM INJECTION USP | 02382385 | Marketed | |
| MIN-OVRAL 21 | 02042320 | Marketed | |
| MIN-OVRAL 28 | 02042339 | Marketed | |
| MYCOBUTIN | 02063786 | Marketed | |
| MYLOTARG | 02494388 | Marketed | |
| NEISVAC-C | 02245057 | Marketed | |
| NGENLA | 02521679 | Marketed | |
| NGENLA | 02521687 | Marketed | |
| NIMENRIX | 02402904 | Marketed | |
| NIVESTYM | 02485575 | Marketed | |
| NIVESTYM | 02485583 | Marketed | |
| NIVESTYM | 02485591 | Marketed | |
| NIVESTYM | 02485656 | Marketed | |
| NURTEC ODT | 02543605 | Marketed | |
| NYVEPRIA | 02506238 | Marketed | |
| OXALIPLATIN | 02444763 | Marketed | |
| OXYTOCIN INJECTION USP | 00497398 | Marketed | |
| PADCEV | 02521903 | Marketed | |
| PADCEV | 02521911 | Marketed | |
| PAMIDRONATE DISODIUM FOR INJECTION | 02244550 | Marketed | |
| PAMIDRONATE DISODIUM FOR INJECTION | 02244551 | Marketed | |
| PAMIDRONATE DISODIUM FOR INJECTION | 02244552 | Marketed | |
| PAXLOVID | 02524031 | Marketed | |
| PENTAMIDINE ISETIONATE FOR INJECTION BP | 02183080 | Marketed | |
| POTASSIUM CHLORIDE FOR INJECTION CONCENTRATE USP | 00037869 | Marketed | |
| PRECEDEX | 02437147 | Marketed | |
| PREMARIN | 02414678 | Marketed | |
| PREMARIN | 02414686 | Marketed | |
| PREMARIN | 02414694 | Marketed | |
| PREMARIN INTRAVENOUS | 02043386 | Marketed | |
| PREMARIN VAGINAL CREAM | 02043440 | Marketed | |
| PREVNAR 20 | 02527049 | Marketed | |
| PRISTIQ | 02321092 | Marketed | |
| PRISTIQ | 02321106 | Marketed | |
| PROSTIN VR STERILE SOLUTION | 00559253 | Marketed | |
| QUELICIN | 00038172 | Marketed | |
| RAPAMUNE | 02243237 | Marketed | |
| RAPAMUNE | 02247111 | Marketed | |
| RUXIENCE | 02495724 | Marketed | |
| SALAZOPYRIN EN-TABS 500 MG | 02064472 | Marketed | |
| SALAZOPYRIN TAB 500MG | 02064480 | Marketed | |
| SELECT 1/35 (21-DAY) | 02197502 | Marketed | |
| SELECT 1/35 (28-DAY) | 02199297 | Marketed | |
| SODIUM BICARBONATE INJECTION USP | 00261998 | Marketed | |
| SODIUM CHLORIDE INJECTION USP | 00037796 | Marketed | |
| SODIUM THIOSULFATE INJECTION USP | 02137186 | Marketed | |
| SOLU-CORTEF | 00030600 | Marketed | |
| SOLU-CORTEF | 00030619 | Marketed | |
| SOLU-CORTEF | 00030627 | Marketed | |
| SOLU-CORTEF | 00030635 | Marketed | |
| SOLU-MEDROL | 00036137 | Marketed | |
| SOLU-MEDROL | 00030678 | Marketed | |
| SOLU-MEDROL | 02367947 | Marketed | |
| SOLU-MEDROL | 02367955 | Marketed | |
| SOLU-MEDROL | 02367963 | Marketed | |
| SOLU-MEDROL | 02367971 | Marketed | |
| SOMAVERT | 02272199 | Marketed | |
| SOMAVERT | 02272202 | Marketed | |
| SOMAVERT | 02272210 | Marketed | |
| SOMAVERT | 02448831 | Marketed | |
| SOMAVERT | 02448858 | Marketed | |
| STERILE WATER FOR INJECTION USP | 02142546 | Marketed | |
| SUTENT | 02280795 | Marketed | |
| SUTENT | 02280809 | Marketed | |
| SUTENT | 02280817 | Marketed | |
| SYNAREL | 02188783 | Marketed | |
| SYNPHASIC 21 TABLETS | 02187108 | Marketed | |
| SYNPHASIC 28 TABLETS | 02187116 | Marketed | |
| TALZENNA | 02492032 | Marketed | |
| TALZENNA | 02555050 | Marketed | |
| TOMUDEX | 02229566 | Marketed | |
| TOPOTECAN HYDROCHLORIDE FOR INJECTION | 02379422 | Marketed | |
| TORISEL | 02304104 | Marketed | |
| TOVIAZ | 02380021 | Marketed | |
| TOVIAZ | 02380048 | Marketed | |
| TPN ELECTROLYTES | 00590215 | Marketed | |
| TRAZIMERA | 02483467 | Marketed | |
| TRAZIMERA | 02483475 | Marketed | |
| TRUMENBA | 02468751 | Marketed | |
| TUKYSA | 02499827 | Marketed | |
| TUKYSA | 02499835 | Marketed | |
| TYGACIL | 02285401 | Marketed | |
| VELSIPITY | 02544903 | Marketed | |
| VFEND | 02256460 | Marketed | |
| VFEND | 02256479 | Marketed | |
| VFEND | 02256487 | Marketed | |
| VFEND | 02279991 | Marketed | |
| VINBLASTINE SULFATE INJECTION | 02183056 | Marketed | |
| VINCRISTINE SULFATE INJECTION USP | 02183013 | Marketed | |
| VYNDAMAX | 02517841 | Marketed | |
| VYNDAQEL | 02495732 | Marketed | |
| XALKORI | 02384256 | Marketed | |
| XALKORI | 02384264 | Marketed | |
| XELJANZ | 02423898 | Marketed | |
| XELJANZ | 02480786 | Marketed | |
| XELJANZ XR | 02470608 | Marketed | |
| XYNTHA | 02309483 | Marketed | |
| XYNTHA | 02309491 | Marketed | |
| XYNTHA SOLOFUSE | 02374064 | Marketed | |
| XYNTHA SOLOFUSE | 02374072 | Marketed | |
| XYNTHA SOLOFUSE | 02374080 | Marketed | |
| XYNTHA SOLOFUSE | 02374099 | Marketed | |
| ZINECARD | 02153432 | Marketed | |
| ZIRABEV | 02489430 | Marketed | |
| ZIRABEV | 02489449 | Marketed | |
| ZYVOXAM | 02243685 | Marketed | |
| ZYVOXAM | 02243686 | Marketed | |
| ABRILADA | 02511088 | Approved | |
| ABRILADA | 02511096 | Approved | |
| ADRIAMYCIN PFS | 02071002 | Dormant | |
| AMINOPHYLLINE INJECTION USP | 00497193 | Dormant | |
| BENEFIX | 02293765 | Dormant | |
| BENEFIX | 02466619 | Approved | |
| BORTEZOMIB FOR INJECTION | 02467011 | Approved | |
| BORTEZOMIB FOR INJECTION | 02480255 | Approved | |
| BORTEZOMIB FOR INJECTION | 02480263 | Approved | |
| DEXTROSE INJECTION USP | 02468506 | Approved | |
| GENOTROPIN | 02401681 | Approved | |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 01901958 | Dormant | |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 02439468 | Dormant | |
| LIDOCAINE HYDROCHLORIDE INJECTION USP | 02490048 | Approved | |
| METHOTREXATE TABLETS, USP | 02562839 | Approved | |
| SODIUM BICARBONATE INJECTION USP | 00261971 | Dormant | |
| TALZENNA | 02492040 | Approved | |
| TALZENNA | 02555069 | Approved | |
| TALZENNA | 02555077 | Approved | |
| XYNTHA | 02309505 | Dormant | |
| XYNTHA | 02309513 | Dormant | |
| XYNTHA SOLOFUSE | 02374056 | Approved | |
| ZINECARD | 02153440 | Dormant | |
| ACCUPRIL 5MG TAB | 01947664 | Cancelled Post Market | |
| ACCUPRIL TAB 10MG | 01947672 | Cancelled Post Market | |
| ACCUPRIL TAB 20MG | 01947680 | Cancelled Post Market | |
| ACCUPRIL TAB 40MG | 01947699 | Cancelled Post Market | |
| ACCURETIC | 02237367 | Cancelled Post Market | |
| ACCURETIC | 02237368 | Cancelled Post Market | |
| ACCURETIC | 02237369 | Cancelled Post Market | |
| ACYCLOVIR SODIUM INJECTION | 02236916 | Cancelled Post Market | |
| ADRIAMYCIN RDF | 02069555 | Cancelled Post Market | |
| ADRIAMYCIN RDF | 02069563 | Cancelled Post Market | |
| ADRIAMYCIN RDF | 02065657 | Cancelled Post Market | |
| ADRUCIL | 02063921 | Cancelled Post Market | |
| ALDACTAZIDE 25 | 00180408 | Cancelled Post Market | |
| ALDACTAZIDE 50 | 00594377 | Cancelled Post Market | |
| ALDACTONE 100 MG | 00285455 | Cancelled Post Market | |
| ALDACTONE 25 MG | 00028606 | Cancelled Post Market | |
| AMIODARONE HYDROCHLORIDE FOR INJECTION | 02245696 | Cancelled Post Market | |
| ANSAID TABLETS 100 MG | 00600792 | Cancelled Post Market | |
| ANSAID TABLETS 50 MG | 00647942 | Cancelled Post Market | |
| ANTIVERT TAB | 00158127 | Cancelled Post Market | |
| ARICEPT RDT | 02269457 | Cancelled Post Market | |
| ARICEPT RDT | 02269465 | Cancelled Post Market |
Showing 300 of 580 drug products. For the rest, search Health Canada’s database.
Notices of Compliance
Newest first.
- VFENDOctober 9, 2026 · NOC 38444 · Supplement to a New Drug Submission (SNDS)
- CYKLOKAPRONOctober 9, 2026 · NOC 38446 · Supplement to a New Drug Submission (SNDS)
- XYNTHA SOLOFUSEOctober 6, 2026 · NOC 38416 · Supplement to a New Drug Submission (SNDS)
- PAXLOVIDAugust 28, 2026 · NOC 38205 · Supplement to a New Drug Submission (SNDS)
- DALACIN C PHOSPHATEAugust 20, 2026 · NOC 38166 · Supplement to a New Drug Submission (SNDS)
- TOVIAZAugust 5, 2026 · NOC 38058 · Supplement to a New Drug Submission (SNDS)
- RAPAMUNEJuly 30, 2026 · NOC 38023 · Supplement to a New Drug Submission (SNDS)
- DIFLUCANJuly 21, 2026 · NOC 37959 · Supplement to a New Drug Submission (SNDS)
- ADCETRISJuly 20, 2026 · NOC 37934 · Supplement to a New Drug Submission (SNDS)
- NGENLAJuly 13, 2026 · NOC 37890 · Supplement to a New Drug Submission (SNDS)
- IDARUBICINJune 30, 2026 · NOC 37815 · New Drug Submission (NDS)
- PADCEVJune 26, 2026 · NOC 37779 · Supplement to a New Drug Submission (SNDS)
- BRAFTOVIJune 24, 2026 · NOC 37776 · Supplement to a New Drug Submission (SNDS)
- DALACIN C FLAVOURED GRANULESJune 23, 2026 · NOC 37766 · Supplement to a New Drug Submission (SNDS)
- MARCAINEJune 17, 2026 · NOC 37723 · Supplement to a New Drug Submission (SNDS)
- BOSULIFJune 2, 2026 · NOC 37650 · Supplement to a New Drug Submission (SNDS)
- DALACIN C PHOSPHATEMay 22, 2026 · NOC 37588 · Supplement to a New Drug Submission (SNDS)
- IXIFIMay 18, 2026 · NOC 37567 · Supplement to a New Drug Submission (SNDS)
- VYNDAQELMay 7, 2026 · NOC 37507 · Supplement to a New Drug Submission (SNDS)
- VYNDAMAXMay 7, 2026 · NOC 37508 · Supplement to a New Drug Submission (SNDS)
- HEMABATEMay 1, 2026 · NOC 37466 · Supplement to a New Drug Submission (SNDS)
- VFENDApril 23, 2026 · NOC 37389 · Supplement to a New Drug Submission (SNDS)
- ABRYSVOApril 20, 2026 · NOC 37393 · Supplement to a New Drug Submission (SNDS)
- NURTEC ODTApril 16, 2026 · NOC 37357 · Supplement to a New Drug Submission (SNDS)
- NURTEC ODTApril 13, 2026 · NOC 37331 · Supplement to a New Drug Submission (SNDS)
- ZYVOXAMApril 10, 2026 · NOC 37322 · Supplement to a New Drug Submission (SNDS)
- XELJANZ; XELJANZ XRApril 9, 2026 · NOC 37314 · Supplement to a New Drug Submission (SNDS)
- INLYTAApril 7, 2026 · NOC 37299 · Supplement to a New Drug Submission (SNDS)
- BREVICON 0.5/35 TABLETS (21 DAY PACK); BREVICON 0.5/35 TABLETS (28 DAY PACK); BREVICON 1/35 TABLETS (21 DAY PACK); BREVICON 1/35 TABLETS (28 DAY PACK)March 26, 2026 · NOC 37194 · Supplement to a New Drug Submission (SNDS)
- DALACIN C FLAVOURED GRANULESMarch 25, 2026 · NOC 37190 · Supplement to a New Drug Submission (SNDS)
- PAXLOVIDMarch 24, 2026 · NOC 37189 · Supplement to a New Drug Submission (SNDS)
- DEPO-PROVERAMarch 11, 2026 · NOC 37084 · Supplement to a New Drug Submission (SNDS)
- PREVNAR 20March 9, 2026 · NOC 37281 · Supplement to a New Drug Submission (SNDS)
- MEKTOVIFebruary 26, 2026 · NOC 36988 · Supplement to a New Drug Submission (SNDS)
- VELSIPITYFebruary 12, 2026 · NOC 36892 · Supplement to a New Drug Submission (SNDS)
- LORBRENAFebruary 11, 2026 · NOC 36885 · Supplement to a New Drug Submission (SNDS)
- TALZENNAFebruary 10, 2026 · NOC 36876 · Supplement to a New Drug Submission (SNDS)
- CIBINQOFebruary 10, 2026 · NOC 36882 · Supplement to a New Drug Submission (SNDS)
- TALZENNAJanuary 26, 2026 · NOC 36788 · Supplement to a New Drug Submission (SNDS)
- MYCOBUTINJanuary 21, 2026 · NOC 36764 · Supplement to a New Drug Submission (SNDS)
- ESTRINGJanuary 8, 2026 · NOC 36701 · Supplement to a New Drug Submission (SNDS)
- PROVERAJanuary 7, 2026 · NOC 36688 · Supplement to a New Drug Submission (SNDS)
- PROSTIN VR STERILE SOLUTIONJanuary 5, 2026 · NOC 36682 · Supplement to a New Drug Submission (SNDS)
- BOSULIFDecember 31, 2025 · NOC 36656 · Supplement to a New Drug Submission (SNDS)
- TRAZIMERADecember 23, 2025 · NOC 36614 · Supplement to a New Drug Submission (SNDS)
- FRAGMINDecember 22, 2025 · NOC 36687 · Supplement to a New Drug Submission (SNDS)
- ATGAMDecember 10, 2025 · NOC 36515 · Supplement to a New Drug Submission (SNDS)
- ABRILADADecember 10, 2025 · NOC 36542 · Supplement to a New Drug Submission (SNDS)
- METHOTREXATE TABLETS, USPDecember 5, 2025 · NOC 36488 · Abbreviated New Drug Submission (ANDS)
- ELREXFIODecember 2, 2025 · NOC 36477 · Supplement to a New Drug Submission (SNDS)
- CYTARABINE INJECTIONNovember 28, 2025 · NOC 36452 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ZIRABEVNovember 28, 2025 · NOC 36458 · Supplement to a New Drug Submission (SNDS)
- TUKYSANovember 24, 2025 · NOC 36417 · New Drug Submission (NDS)
- VELSIPITYNovember 17, 2025 · NOC 36391 · Supplement to a New Drug Submission (SNDS)
- XELJANZ; XELJANZ XRNovember 14, 2025 · NOC 36374 · Supplement to a New Drug Submission (SNDS)
- ALDACTONENovember 7, 2025 · NOC 36349 · Supplement to a New Drug Submission (SNDS)
- TYGACILNovember 4, 2025 · NOC 36323 · Supplement to a New Drug Submission (SNDS)
- IXIFIOctober 20, 2025 · NOC 36211 · Supplement to a New Drug Submission (SNDS)
- ABRYSVOOctober 17, 2025 · NOC 36224 · Supplement to a New Drug Submission (SNDS)
- EUCRISAOctober 16, 2025 · NOC 36194 · Supplement to a New Drug Submission (SNDS)
- ADCETRISOctober 9, 2025 · NOC 36134 · New Drug Submission (NDS)
- ELREXFIOOctober 3, 2025 · NOC 36102 · Supplement to a New Drug Submission (SNDS)
- PREVNAR 20September 29, 2025 · NOC 36098 · Supplement to a New Drug Submission (SNDS)
- ABRYSVOSeptember 26, 2025 · NOC 36070 · Supplement to a New Drug Submission (SNDS)
- PADCEVSeptember 19, 2025 · NOC 36036 · New Drug Submission (NDS)
- METHOTREXATE TABLETS, USPSeptember 9, 2025 · NOC 35979 · Supplement to a New Drug Submission (SNDS)
- SELECT 1/35 (21-DAY); SELECT 1/35 (28-DAY)August 29, 2025 · NOC 35934 · Supplement to a New Drug Submission (SNDS)
- SYNPHASIC 21 TABLETS; SYNPHASIC 28 TABLETSAugust 29, 2025 · NOC 35935 · Supplement to a New Drug Submission (SNDS)
- MIN-OVRAL 21; MIN-OVRAL 28August 25, 2025 · NOC 35899 · Supplement to a New Drug Submission (SNDS)
- BREVICON 0.5/35 TABLETS (21 DAY PACK); BREVICON 1/35 TABLETS (21 DAY PACK)August 7, 2025 · NOC 35799 · Supplement to a New Drug Submission (SNDS)
- PAXLOVIDAugust 1, 2025 · NOC 35786 · Supplement to a New Drug Submission (SNDS)
- RAPAMUNEJuly 25, 2025 · NOC 35741 · Supplement to a New Drug Submission (SNDS)
- BRAFTOVIJuly 25, 2025 · NOC 35751 · Supplement to a New Drug Submission (SNDS)
- DEPO-MEDROL WITH LIDOCAINEJuly 4, 2025 · NOC 35630 · Supplement to a New Drug Submission (SNDS)
- IBRANCEJuly 4, 2025 · NOC 35631 · Supplement to a New Drug Submission (SNDS)
- PREMARINJune 27, 2025 · NOC 35591 · Supplement to a New Drug Submission (SNDS)
- DEPO-MEDROL; DEPO-MEDROL (WITH PRESERVATIVE)June 19, 2025 · NOC 35541 · Supplement to a New Drug Submission (SNDS)
- SOLU-MEDROLJune 19, 2025 · NOC 35542 · Supplement to a New Drug Submission (SNDS)
- MEDROLJune 13, 2025 · NOC 35516 · Supplement to a New Drug Submission (SNDS)
- FRAGMINJune 6, 2025 · NOC 35484 · Supplement to a New Drug Submission (SNDS)
- VFENDMay 23, 2025 · NOC 35407 · Supplement to a New Drug Submission (SNDS)
- LEUCOVORIN CALCIUM INJECTION USPApril 28, 2025 · NOC 35251 · Supplement to a New Drug Submission (SNDS)
- DUAVIVEApril 25, 2025 · NOC 35249 · Supplement to a New Drug Submission (SNDS)
- HYDROMORPHONE HYDROCHLORIDE INJECTION USPApril 24, 2025 · NOC 35238 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NIMENRIXApril 23, 2025 · NOC 35254 · Supplement to a New Drug Submission (SNDS)
- IBRANCEMarch 24, 2025 · NOC 35054 · Supplement to a New Drug Submission (SNDS)
- PAXLOVIDMarch 20, 2025 · NOC 35057 · Supplement to a New Drug Submission (SNDS)
- VELSIPITYMarch 18, 2025 · NOC 35040 · Supplement to a New Drug Submission (SNDS)
- KETOROLAC TROMETHAMINE INJECTION USPMarch 7, 2025 · NOC 34971 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PROVERAFebruary 17, 2025 · NOC 34861 · Supplement to a New Drug Submission (SNDS)
- ATGAMJanuary 31, 2025 · NOC 34775 · Supplement to a New Drug Submission (SNDS)
- TALZENNAJanuary 30, 2025 · NOC 34763 · Supplement to a New Drug Submission (SNDS)
- SOLU-MEDROLJanuary 30, 2025 · NOC 34765 · Supplement to a New Drug Submission (SNDS)
- MEDROLJanuary 27, 2025 · NOC 34748 · Supplement to a New Drug Submission (SNDS)
- DEPO-MEDROL WITH LIDOCAINEJanuary 24, 2025 · NOC 34745 · Supplement to a New Drug Submission (SNDS)
- LITFULOJanuary 17, 2025 · NOC 34726 · Supplement to a New Drug Submission (SNDS)
- DOXORUBICIN HYDROCHLORIDE FOR INJECTION USPJanuary 9, 2025 · NOC 34654 · Supplement to a New Drug Submission (SNDS)
- IBRANCEDecember 20, 2024 · NOC 34590 · Supplement to a New Drug Submission (SNDS)
- MARCAINE EDecember 12, 2024 · NOC 34544 · Supplement to a New Drug Submission (SNDS)
- VINBLASTINE SULFATE INJECTIONDecember 5, 2024 · NOC 34504 · Supplement to a New Drug Submission (SNDS)
The latest 100 of 1,004.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- Canadian labelling for all JAK inhibitors to include risks of serious heart-related problems, fatal blood clots and cancerNovember 1, 2022 · Drugs · Labelling
- Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and MalignancyOctober 31, 2022 · Drugs · New safety information - Product safety
- Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurityApril 21, 2022 · Drugs · Contamination
- Accupril Tabs: Nitrosamine impurityApril 20, 2022 · Drugs · Contamination · Type I
- Accuretic (quinapril hydrochloride and hydrochlorothiazide): Nitrosamine ImpurityMarch 4, 2022 · Drugs · Contamination · Type I
- Inderal-LA: Nitrosamine ImpurityMarch 2, 2022 · Drugs · Contamination · Type I
- Pfizer recalls Inderal-LA (propranolol hydrochloride) capsules due to a nitrosamine impurityMarch 1, 2022 · Drugs · Contamination
- XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and InfectionJanuary 12, 2022 · Drugs · New safety information - Product safety
- Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancerJanuary 12, 2022 · Drugs · Product safety
- CHAMPIX (varenicline) — Potential Risk Posed by Long-Term Exposure to Nitrosamine Impurity, N-nitrosovarenicline, Exceeding Acceptable Intake LimitJune 30, 2021 · Drugs · Product safety
- Pfizer Champix Product Recall (2021-06-08)June 8, 2021 · Drugs · Product safety · Type II
- Duavive (2020-05-20)May 20, 2020 · Drugs · Product safety · Type II
- Importation of US-Labelled QUELICIN (succinylcholine chloride injection) due to Shortage of Canadian-labelled QUELICINApril 29, 2020 · Drugs · Product safety
- XELJANZ / XELJANZ XR (tofacitinib) - Risk of ThrombosisDecember 2, 2019 · Drugs · Product safety
- Demulen 30 birth control pills: Packages containing broken or chipped pillsJune 1, 2018 · Drugs
- ALESSE 21 and ALESSE 28: Packages Containing Broken or Split TabletsDecember 11, 2017 · Drugs · Product quality - Product safety
- Alesse 21 and 28 birth control pill: Packages may contain broken or smaller-than-normal pills, which may reduce effectiveness in preventing pregnancyDecember 1, 2017 · Drugs · Labelling
- SOLU-MEDROL ACT-O-VIAL 40 mg - Risk of Hypersensitivity in Individuals Allergic to Cow's MilkSeptember 6, 2017 · Drugs
- LEVOPHED 1.0 mg/mL (2017-05-15)June 22, 2017 · Drugs · Product safety · Type II
- Solu-CORTEF 100 mg Act-O-Vial (2016-07-22)August 3, 2016 · Drugs · Product safety · Type II
- Solu-Cortef (hydrocortisone sodium succinate for injection) 100 mg/2 mL single-dose Act-O-Vial - Recalled Lots due to Potential for Dosing ErrorAugust 2, 2016 · Drugs · Product safety
- BICILLIN L-A Injection (penicillin G benzathine) 2 mL Single Use Syringe - Shortage and Replacement with Australian Labelled StockMay 12, 2016 · Drugs
- Alesse 21 (2015-04-02)April 9, 2015 · Drugs · Product safety · Type I
- One lot of expired Alesse 21 birth control recalled by Shoppers Drug MartApril 7, 2015 · Drugs
- Alzheimer's drug Aricept (donepezil) - New warnings on the serious risks of muscle breakdown and of a neurological disorderJanuary 21, 2015 · Drugs · Labelling - New safety information - Product safety
- Torisel (2014-10-06)October 22, 2014 · Drugs · Product safety · Type III
- Solu-Medrol 1G solvent 8mL Act-O-Vial (2013-12-23)January 6, 2014 · Drugs · Product safety · Type III
- Propofol-II Injectable Emulsion 1%, (10mg/mL), 1000mg/100mL - Recall of Lot No. 29609DJ Due to Presence of Particulate Matter - For Health ProfessionalsNovember 27, 2013 · Drugs · Product safety
- Sutent (sunitinib malate) - Cases of Severe Skin Reactions - For the PublicSeptember 6, 2013 · Drugs · Product safety
- Sutent (sunitinib malate) - Cases of Severe Skin Reactions - For Health ProfessionalsSeptember 6, 2013 · Drugs · Product safety
- CHAMPIX (varenicline tartrate) and ZYBAN (bupropion hydrochloride) - Revision to the Consumer Information of Non-Nicotine Smoking Cessation Aids - For Health ProfessionalsMay 30, 2013 · Drugs · Product safety
- CHAMPIX (varenicline tartrate) and ZYBAN (bupropion hydrochloride) - Revision to the Consumer Information of Non-Nicotine Smoking Cessation Aids - For the PublicMay 30, 2013 · Drugs · Product safety
- Zithromax/Zmax SR (azithromycin) - Risk of Potentially Fatal Irregular Heart Beats - For the PublicMay 16, 2013 · Drugs
- Zithromax/Zmax SR (azithromycin) - Risk of Potentially Fatal Irregular Heart Beats - For Health ProfessionalsMay 16, 2013 · Drugs
- Champix: Updated safety information for the smoking-cessation drugJanuary 19, 2012 · Drugs · Product safety
- Thelin (sitaxsentan sodium) - Worldwide Product Withdrawal - For the PublicDecember 20, 2010 · Drugs
- Thelin (sitaxsentan sodium) - Worldwide Product Withdrawal - For Health ProfessionalsDecember 20, 2010 · Drugs
- Champix (varenicline tartrate) - Changes to the Canadian Product Monograph - For Health ProfessionalsJune 3, 2010 · Drugs
- CHAMPIX (varenicline tartrate) - Changes to the Canadian Product Monograph - For the PublicJune 3, 2010 · Drugs
- Rapamune (sirolimus) - Blood Level Measurement Changes - For Health ProfessionalsDecember 2, 2009 · Drugs
- Archived - Rapamune (sirolimus) - Blood Level Measurement Changes - For the PublicDecember 2, 2009 · Drugs
- Archived - New warning regarding RAPAMUNE® (sirolimus) and Bronchial Anastomotic Dehiscence including fatal cases by Wyeth PharmaceuticalsFebruary 23, 2009 · Health products
- Archived – Health Canada Determines Viracept (nelfinavir mesylate) Can Be Used Again In Non-Pregnant HIV-Infected Adults and ChildrenAugust 21, 2008 · Drugs
- Association between Torisel (temsirolimus) concentrate for injection and hypersensitivity/infusion reactions- For Health ProfessionalsAugust 11, 2008 · Drugs
- Archived - Association between TORISEL (temsirolimus) concentrate for injection and hypersensitivity/infusion reactions - For the PublicAugust 11, 2008 · Drugs
- New safety information regarding Champix (varenicline tartrate) - For Health ProfessionalsJune 20, 2008 · Drugs
- Important Safety Information on VIRACEPT (nelfinavir mesylate) - For Health ProfessionalsSeptember 10, 2007 · Drugs
- Important Safety Information on THELIN (sitaxsentan sodium) - For Health ProfessionalsAugust 23, 2007 · Drugs
- Archived - Association of Macugen (pegaptanib sodium injection) with hypersensitivity reactions - For the PublicJanuary 23, 2006 · Drugs
- Archived - Association of Macugen (pegaptanib sodium injection) with hypersensitivity reactionsJanuary 23, 2006 · Drugs
- Potential Effect of DEPO-PROVERA (medroxyprogesterone acetate injectable suspension, USP) on Bone Mineral Density changes in adults and adolescents - Pfizer Canada Inc.July 7, 2005 · Drugs
- Archived – Association of Tazocin® (Piperacillin/Tazobactam) with False Positive Results of the Bio-Rad Aspergillus AssayMarch 9, 2004 · Drugs · Product safety
- Archived - Important Information - CamptosarMay 11, 2001 · Drugs